Abstract
Alzheimers Disease (AD) is a progressive and devastating neurodegenerative disorder affecting the brain. It is the most common form of late-life dementia and is one of the leading causes of death in the developed world. Due to the ageing population and improvement in diagnosis it is expected that the number of diagnosed AD patients will increase from the current level of ∼5 million to ∼22 million by 2025. Acetylcholine-based therapies, currently the only treatment regimes approved for AD, will also be the basis for treatment in the near future. However, progression of the disease is not affected by acetylcholinesterase inhibitors; rather it is a symptomatic treatment which can delay deterioration of cognitive symptoms for up to six months. Pharmaceutical companies are now investing their efforts in the development of diseasemodifying treatments for AD. The rationale for new drug design is based on the amyloid cascade hypothesis, which proposes that accumulation of amyloid beta peptide is the key event that triggers the pathological events in AD. The most promising, emerging approaches for the treatment of AD, targeting the release, the aggregation and the clearance of Abeta will be discussed.
Keywords: alzheimer disease, amyloid cascade hypothesis, amyloid beta peptide, amyloid precursor protein, disease modifying therapeutic
Current Neuropharmacology
Title: Disease Modifying Therapeutic Strategies in Alzheimers Disease Targeting the Amyloid Cascade
Volume: 2 Issue: 3
Author(s): Christian Czech and Celine Adessi
Affiliation:
Keywords: alzheimer disease, amyloid cascade hypothesis, amyloid beta peptide, amyloid precursor protein, disease modifying therapeutic
Abstract: Alzheimers Disease (AD) is a progressive and devastating neurodegenerative disorder affecting the brain. It is the most common form of late-life dementia and is one of the leading causes of death in the developed world. Due to the ageing population and improvement in diagnosis it is expected that the number of diagnosed AD patients will increase from the current level of ∼5 million to ∼22 million by 2025. Acetylcholine-based therapies, currently the only treatment regimes approved for AD, will also be the basis for treatment in the near future. However, progression of the disease is not affected by acetylcholinesterase inhibitors; rather it is a symptomatic treatment which can delay deterioration of cognitive symptoms for up to six months. Pharmaceutical companies are now investing their efforts in the development of diseasemodifying treatments for AD. The rationale for new drug design is based on the amyloid cascade hypothesis, which proposes that accumulation of amyloid beta peptide is the key event that triggers the pathological events in AD. The most promising, emerging approaches for the treatment of AD, targeting the release, the aggregation and the clearance of Abeta will be discussed.
Export Options
About this article
Cite this article as:
Czech Christian and Adessi Celine, Disease Modifying Therapeutic Strategies in Alzheimers Disease Targeting the Amyloid Cascade, Current Neuropharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570159043359666
DOI https://dx.doi.org/10.2174/1570159043359666 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design Altered Arginine Metabolism in Cells Transfected with Human Wild-Type Beta Amyloid Precursor Protein (βAPP)
Current Alzheimer Research Brief but Chronic Increase in Allopregnanolone Cause Accelerated AD Pathology Differently in Two Mouse Models
Current Alzheimer Research α-Synuclein and the Pathogenesis of Parkinsons Disease
Protein & Peptide Letters Involvement of the Septo-Hippocampal Cholinergic Pathway in Association with Septal Acetylcholinesterase Upregulation in a Mouse Model of Tauopathy
Current Alzheimer Research Synthesis, Characterization and Physico-chemical Properties of New 2-(4- Arylpiperazine-1-yl)-1-(3-methylbenzofuran-2-yl)ethanoles as Potential Antihypertensive Agents
Current Organic Chemistry Sleep Disturbance is Associated with Incident Dementia and Mortality
Current Alzheimer Research Intrinsically Disordered Domains, Amyloids and Protein Liquid Phases: Evolving Concepts and Open Questions
Protein & Peptide Letters Molecular Biomarkers in Schizophrenia – Implications for Clinical Practice
Current Psychiatry Reviews The Role of MAPK's Signaling in Mediating ApoE4-Driven Pathology In Vivo
Current Alzheimer Research Is High Oral Dose L-arginine Intake Effective in Leukoaraiosis? Preliminary Data, Study Protocol and Expert’s Opinion
Current Aging Science Advantages of Structure-Based Drug Design Approaches in Neurological Disorders
Current Neuropharmacology Alzheimers Disease: Interactions Between Cholinergic Functions and β- amyloid
Current Alzheimer Research Anorexia of Aging
Current Nutrition & Food Science COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning
Current Pharmaceutical Design Pleiotropic Effects of PPARγ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus
Current Vascular Pharmacology Multi-potent Natural Scaffolds Targeting Amyloid Cascade: In Search of Alzheimer's Disease Therapeutics
Current Topics in Medicinal Chemistry Upregulated Long Non-coding RNA ALMS1-IT1 Promotes Neuroinflammation by Activating NF-κB Signaling in Ischemic Cerebral Injury
Current Pharmaceutical Design Diagnosis of Mild Cognitive Impairment Using Cognitive Tasks: A Functional Near-Infrared Spectroscopy Study
Current Alzheimer Research